Safety and immunogenicity of live attenuated human–bovine (UK) reassortant rotavirus vaccines with VP7-specificity for serotypes 1, 2, 3 or 4 in adults, children and infants
Live rotavirus vaccine candidates representing VP7 serotypes 1, 2, 3 or 4 derived by reassortment between bovine UK rotavirus and human rotavirus strains D, DS-1, P or ST3 were evaluated for safety and immunogenicity in adults, children and infants. Infection was defined by evidence of rotavirus she...
Gespeichert in:
| Veröffentlicht in: | Vaccine 1999-06, Vol.17 (20), p.2715-2725 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2725 |
|---|---|
| container_issue | 20 |
| container_start_page | 2715 |
| container_title | Vaccine |
| container_volume | 17 |
| creator | Clements-Mann, Mary Lou Makhene, Mamodikoe K Mrukowicz, Jacek Wright, Peter F Hoshino, Yasutaka Midthun, Karen Sperber, Ellen Karron, Ruth Kapikian, Albert Z |
| description | Live rotavirus vaccine candidates representing VP7 serotypes 1, 2, 3 or 4 derived by reassortment between bovine UK rotavirus and human rotavirus strains D, DS-1, P or ST3 were evaluated for safety and immunogenicity in adults, children and infants. Infection was defined by evidence of rotavirus shed in stools or a 4-fold or greater increase in serum rotavirus-specific IgA or IgG ELISA or plaque reduction neutralization antibody. A single oral dose (10
5.3 or 10
5.8 pfu) of reassortant virus was well tolerated and infected most infants: 10/20 (50%) by D×UK; 9/11 (82%) by DS-1×UK; 8/10 (80%) by P×UK and 13/14 (93%) by ST3×UK. All 14 infants given two doses of D×UK were infected. These findings demonstrating satisfactory levels of attenuation, safety, infectivity and immunogenicity of each reassortant in infants warrant additional studies of a candidate vaccine containing these four strains. |
| doi_str_mv | 10.1016/S0264-410X(98)00497-6 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_69913195</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0264410X98004976</els_id><sourcerecordid>69913195</sourcerecordid><originalsourceid>FETCH-LOGICAL-e292t-92455e84599c4afcf468d1453cac670f92d552a628261c6d1c17ac612d2a45843</originalsourceid><addsrcrecordid>eNpF0d1uFCEUB3BiNHatPoKGC2PaZEeBYRi4MqbxKzbRpNZ4RygcXMwMswIzZu98Bx_Ed_JJpN1Vr0gOvxw454_QQ0qeUkLFswvCBG84JZ9PlDwlhKu-EbfQisq-bVhH5W20-keO0L2cvxJCupaqu-iIEk6lYu0K_bowHsoOm-hwGMc5Tl8gBhtqafJ4CAtgUwrE2RRweDOPJv7-8fNqWkIEfHL57hQnMDlPqZhYcJqKWUKaM16MtZVk_D2UDf70oW_yFmzw-9Z-SjhD1bttJXSN2Rq3uBY5DhEbNw8lr7HdhMEliPvPRV9fyPfRHW-GDA8O5zG6fPXy49mb5vz967dnL84bYIqVRjHedSB5p5TlxlvPhXSUd601VvTEK-a6jhnBJBPUCkct7esNZY4Z3kneHqMn-77bNH2bIRc9hmxhGEyEac5aKEXrLrsKHx3gfDWC09sURpN2-u-KK3h8ACZbM_hkog35v5O9kKqv7PmeQZ1qCZB0tgGiBRcS2KLdFGpPfZ29vsleXwerldQ32WvR_gFXhqI8</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>69913195</pqid></control><display><type>article</type><title>Safety and immunogenicity of live attenuated human–bovine (UK) reassortant rotavirus vaccines with VP7-specificity for serotypes 1, 2, 3 or 4 in adults, children and infants</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Clements-Mann, Mary Lou ; Makhene, Mamodikoe K ; Mrukowicz, Jacek ; Wright, Peter F ; Hoshino, Yasutaka ; Midthun, Karen ; Sperber, Ellen ; Karron, Ruth ; Kapikian, Albert Z</creator><creatorcontrib>Clements-Mann, Mary Lou ; Makhene, Mamodikoe K ; Mrukowicz, Jacek ; Wright, Peter F ; Hoshino, Yasutaka ; Midthun, Karen ; Sperber, Ellen ; Karron, Ruth ; Kapikian, Albert Z</creatorcontrib><description>Live rotavirus vaccine candidates representing VP7 serotypes 1, 2, 3 or 4 derived by reassortment between bovine UK rotavirus and human rotavirus strains D, DS-1, P or ST3 were evaluated for safety and immunogenicity in adults, children and infants. Infection was defined by evidence of rotavirus shed in stools or a 4-fold or greater increase in serum rotavirus-specific IgA or IgG ELISA or plaque reduction neutralization antibody. A single oral dose (10
5.3 or 10
5.8 pfu) of reassortant virus was well tolerated and infected most infants: 10/20 (50%) by D×UK; 9/11 (82%) by DS-1×UK; 8/10 (80%) by P×UK and 13/14 (93%) by ST3×UK. All 14 infants given two doses of D×UK were infected. These findings demonstrating satisfactory levels of attenuation, safety, infectivity and immunogenicity of each reassortant in infants warrant additional studies of a candidate vaccine containing these four strains.</description><identifier>ISSN: 0264-410X</identifier><identifier>EISSN: 1873-2518</identifier><identifier>DOI: 10.1016/S0264-410X(98)00497-6</identifier><identifier>PMID: 10418923</identifier><identifier>CODEN: VACCDE</identifier><language>eng</language><publisher>Oxford: Elsevier Ltd</publisher><subject>Adolescent ; Adult ; Alanine Transaminase - blood ; Animals ; Antibodies, Viral - blood ; Antigens, Viral ; Biological and medical sciences ; Capsid - immunology ; Capsid Proteins ; Cattle ; Child, Preschool ; Diarrheal vaccines ; Epidemiology. Vaccinations ; Fundamental and applied biological sciences. Psychology ; General aspects ; Humans ; Human–bovine reassortant rotavirus vaccines ; Immunization, Secondary ; Infant ; Infectious diseases ; Live attenuated virus vaccines ; Medical sciences ; Microbiology ; Middle Aged ; Pediatric vaccines ; Rotavirus - immunology ; Rotavirus vaccines ; Serotyping ; Vaccination ; Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies ; Vaccines, Attenuated - adverse effects ; Vaccines, Attenuated - immunology ; Vaccines, Synthetic - immunology ; Viral Vaccines - adverse effects ; Viral Vaccines - immunology ; Virology</subject><ispartof>Vaccine, 1999-06, Vol.17 (20), p.2715-2725</ispartof><rights>1999 Elsevier Science Ltd</rights><rights>1999 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0264410X98004976$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=1876897$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/10418923$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Clements-Mann, Mary Lou</creatorcontrib><creatorcontrib>Makhene, Mamodikoe K</creatorcontrib><creatorcontrib>Mrukowicz, Jacek</creatorcontrib><creatorcontrib>Wright, Peter F</creatorcontrib><creatorcontrib>Hoshino, Yasutaka</creatorcontrib><creatorcontrib>Midthun, Karen</creatorcontrib><creatorcontrib>Sperber, Ellen</creatorcontrib><creatorcontrib>Karron, Ruth</creatorcontrib><creatorcontrib>Kapikian, Albert Z</creatorcontrib><title>Safety and immunogenicity of live attenuated human–bovine (UK) reassortant rotavirus vaccines with VP7-specificity for serotypes 1, 2, 3 or 4 in adults, children and infants</title><title>Vaccine</title><addtitle>Vaccine</addtitle><description>Live rotavirus vaccine candidates representing VP7 serotypes 1, 2, 3 or 4 derived by reassortment between bovine UK rotavirus and human rotavirus strains D, DS-1, P or ST3 were evaluated for safety and immunogenicity in adults, children and infants. Infection was defined by evidence of rotavirus shed in stools or a 4-fold or greater increase in serum rotavirus-specific IgA or IgG ELISA or plaque reduction neutralization antibody. A single oral dose (10
5.3 or 10
5.8 pfu) of reassortant virus was well tolerated and infected most infants: 10/20 (50%) by D×UK; 9/11 (82%) by DS-1×UK; 8/10 (80%) by P×UK and 13/14 (93%) by ST3×UK. All 14 infants given two doses of D×UK were infected. These findings demonstrating satisfactory levels of attenuation, safety, infectivity and immunogenicity of each reassortant in infants warrant additional studies of a candidate vaccine containing these four strains.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Alanine Transaminase - blood</subject><subject>Animals</subject><subject>Antibodies, Viral - blood</subject><subject>Antigens, Viral</subject><subject>Biological and medical sciences</subject><subject>Capsid - immunology</subject><subject>Capsid Proteins</subject><subject>Cattle</subject><subject>Child, Preschool</subject><subject>Diarrheal vaccines</subject><subject>Epidemiology. Vaccinations</subject><subject>Fundamental and applied biological sciences. Psychology</subject><subject>General aspects</subject><subject>Humans</subject><subject>Human–bovine reassortant rotavirus vaccines</subject><subject>Immunization, Secondary</subject><subject>Infant</subject><subject>Infectious diseases</subject><subject>Live attenuated virus vaccines</subject><subject>Medical sciences</subject><subject>Microbiology</subject><subject>Middle Aged</subject><subject>Pediatric vaccines</subject><subject>Rotavirus - immunology</subject><subject>Rotavirus vaccines</subject><subject>Serotyping</subject><subject>Vaccination</subject><subject>Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies</subject><subject>Vaccines, Attenuated - adverse effects</subject><subject>Vaccines, Attenuated - immunology</subject><subject>Vaccines, Synthetic - immunology</subject><subject>Viral Vaccines - adverse effects</subject><subject>Viral Vaccines - immunology</subject><subject>Virology</subject><issn>0264-410X</issn><issn>1873-2518</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1999</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpF0d1uFCEUB3BiNHatPoKGC2PaZEeBYRi4MqbxKzbRpNZ4RygcXMwMswIzZu98Bx_Ed_JJpN1Vr0gOvxw454_QQ0qeUkLFswvCBG84JZ9PlDwlhKu-EbfQisq-bVhH5W20-keO0L2cvxJCupaqu-iIEk6lYu0K_bowHsoOm-hwGMc5Tl8gBhtqafJ4CAtgUwrE2RRweDOPJv7-8fNqWkIEfHL57hQnMDlPqZhYcJqKWUKaM16MtZVk_D2UDf70oW_yFmzw-9Z-SjhD1bttJXSN2Rq3uBY5DhEbNw8lr7HdhMEliPvPRV9fyPfRHW-GDA8O5zG6fPXy49mb5vz967dnL84bYIqVRjHedSB5p5TlxlvPhXSUd601VvTEK-a6jhnBJBPUCkct7esNZY4Z3kneHqMn-77bNH2bIRc9hmxhGEyEac5aKEXrLrsKHx3gfDWC09sURpN2-u-KK3h8ACZbM_hkog35v5O9kKqv7PmeQZ1qCZB0tgGiBRcS2KLdFGpPfZ29vsleXwerldQ32WvR_gFXhqI8</recordid><startdate>19990604</startdate><enddate>19990604</enddate><creator>Clements-Mann, Mary Lou</creator><creator>Makhene, Mamodikoe K</creator><creator>Mrukowicz, Jacek</creator><creator>Wright, Peter F</creator><creator>Hoshino, Yasutaka</creator><creator>Midthun, Karen</creator><creator>Sperber, Ellen</creator><creator>Karron, Ruth</creator><creator>Kapikian, Albert Z</creator><general>Elsevier Ltd</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>19990604</creationdate><title>Safety and immunogenicity of live attenuated human–bovine (UK) reassortant rotavirus vaccines with VP7-specificity for serotypes 1, 2, 3 or 4 in adults, children and infants</title><author>Clements-Mann, Mary Lou ; Makhene, Mamodikoe K ; Mrukowicz, Jacek ; Wright, Peter F ; Hoshino, Yasutaka ; Midthun, Karen ; Sperber, Ellen ; Karron, Ruth ; Kapikian, Albert Z</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-e292t-92455e84599c4afcf468d1453cac670f92d552a628261c6d1c17ac612d2a45843</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1999</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Alanine Transaminase - blood</topic><topic>Animals</topic><topic>Antibodies, Viral - blood</topic><topic>Antigens, Viral</topic><topic>Biological and medical sciences</topic><topic>Capsid - immunology</topic><topic>Capsid Proteins</topic><topic>Cattle</topic><topic>Child, Preschool</topic><topic>Diarrheal vaccines</topic><topic>Epidemiology. Vaccinations</topic><topic>Fundamental and applied biological sciences. Psychology</topic><topic>General aspects</topic><topic>Humans</topic><topic>Human–bovine reassortant rotavirus vaccines</topic><topic>Immunization, Secondary</topic><topic>Infant</topic><topic>Infectious diseases</topic><topic>Live attenuated virus vaccines</topic><topic>Medical sciences</topic><topic>Microbiology</topic><topic>Middle Aged</topic><topic>Pediatric vaccines</topic><topic>Rotavirus - immunology</topic><topic>Rotavirus vaccines</topic><topic>Serotyping</topic><topic>Vaccination</topic><topic>Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies</topic><topic>Vaccines, Attenuated - adverse effects</topic><topic>Vaccines, Attenuated - immunology</topic><topic>Vaccines, Synthetic - immunology</topic><topic>Viral Vaccines - adverse effects</topic><topic>Viral Vaccines - immunology</topic><topic>Virology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Clements-Mann, Mary Lou</creatorcontrib><creatorcontrib>Makhene, Mamodikoe K</creatorcontrib><creatorcontrib>Mrukowicz, Jacek</creatorcontrib><creatorcontrib>Wright, Peter F</creatorcontrib><creatorcontrib>Hoshino, Yasutaka</creatorcontrib><creatorcontrib>Midthun, Karen</creatorcontrib><creatorcontrib>Sperber, Ellen</creatorcontrib><creatorcontrib>Karron, Ruth</creatorcontrib><creatorcontrib>Kapikian, Albert Z</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Vaccine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Clements-Mann, Mary Lou</au><au>Makhene, Mamodikoe K</au><au>Mrukowicz, Jacek</au><au>Wright, Peter F</au><au>Hoshino, Yasutaka</au><au>Midthun, Karen</au><au>Sperber, Ellen</au><au>Karron, Ruth</au><au>Kapikian, Albert Z</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Safety and immunogenicity of live attenuated human–bovine (UK) reassortant rotavirus vaccines with VP7-specificity for serotypes 1, 2, 3 or 4 in adults, children and infants</atitle><jtitle>Vaccine</jtitle><addtitle>Vaccine</addtitle><date>1999-06-04</date><risdate>1999</risdate><volume>17</volume><issue>20</issue><spage>2715</spage><epage>2725</epage><pages>2715-2725</pages><issn>0264-410X</issn><eissn>1873-2518</eissn><coden>VACCDE</coden><abstract>Live rotavirus vaccine candidates representing VP7 serotypes 1, 2, 3 or 4 derived by reassortment between bovine UK rotavirus and human rotavirus strains D, DS-1, P or ST3 were evaluated for safety and immunogenicity in adults, children and infants. Infection was defined by evidence of rotavirus shed in stools or a 4-fold or greater increase in serum rotavirus-specific IgA or IgG ELISA or plaque reduction neutralization antibody. A single oral dose (10
5.3 or 10
5.8 pfu) of reassortant virus was well tolerated and infected most infants: 10/20 (50%) by D×UK; 9/11 (82%) by DS-1×UK; 8/10 (80%) by P×UK and 13/14 (93%) by ST3×UK. All 14 infants given two doses of D×UK were infected. These findings demonstrating satisfactory levels of attenuation, safety, infectivity and immunogenicity of each reassortant in infants warrant additional studies of a candidate vaccine containing these four strains.</abstract><cop>Oxford</cop><pub>Elsevier Ltd</pub><pmid>10418923</pmid><doi>10.1016/S0264-410X(98)00497-6</doi><tpages>11</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0264-410X |
| ispartof | Vaccine, 1999-06, Vol.17 (20), p.2715-2725 |
| issn | 0264-410X 1873-2518 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_69913195 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Adolescent Adult Alanine Transaminase - blood Animals Antibodies, Viral - blood Antigens, Viral Biological and medical sciences Capsid - immunology Capsid Proteins Cattle Child, Preschool Diarrheal vaccines Epidemiology. Vaccinations Fundamental and applied biological sciences. Psychology General aspects Humans Human–bovine reassortant rotavirus vaccines Immunization, Secondary Infant Infectious diseases Live attenuated virus vaccines Medical sciences Microbiology Middle Aged Pediatric vaccines Rotavirus - immunology Rotavirus vaccines Serotyping Vaccination Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies Vaccines, Attenuated - adverse effects Vaccines, Attenuated - immunology Vaccines, Synthetic - immunology Viral Vaccines - adverse effects Viral Vaccines - immunology Virology |
| title | Safety and immunogenicity of live attenuated human–bovine (UK) reassortant rotavirus vaccines with VP7-specificity for serotypes 1, 2, 3 or 4 in adults, children and infants |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-11T12%3A20%3A52IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Safety%20and%20immunogenicity%20of%20live%20attenuated%20human%E2%80%93bovine%20(UK)%20reassortant%20rotavirus%20vaccines%20with%20VP7-specificity%20for%20serotypes%201,%202,%203%20or%204%20in%20adults,%20children%20and%20infants&rft.jtitle=Vaccine&rft.au=Clements-Mann,%20Mary%20Lou&rft.date=1999-06-04&rft.volume=17&rft.issue=20&rft.spage=2715&rft.epage=2725&rft.pages=2715-2725&rft.issn=0264-410X&rft.eissn=1873-2518&rft.coden=VACCDE&rft_id=info:doi/10.1016/S0264-410X(98)00497-6&rft_dat=%3Cproquest_pubme%3E69913195%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=69913195&rft_id=info:pmid/10418923&rft_els_id=S0264410X98004976&rfr_iscdi=true |